September 13th, 2022 | 11 a.m. CT/12:00 noon ET
Hosted by Sandra Fryhofer, MD, Chair, AMA Board of Trustees
- Adam Sherwat, MD, Deputy Director, Office of Infectious Disease at FDA’s Center for Drug Evaluation and Research
- Brett W. Petersen, MD, MPH, Deputy Chief, Poxvirus and Rabies Branch, CDC’s Division of High-Consequence Pathogens and Pathology
Join experts from the AMA, FDA, and CDC for a discussion about tecovirimat, or TPOXX, for the treatment of monkeypox in infected individuals. The discussion will provide background on tecovirimat, including its current status, availability and access while the drug is under an investigational new drug application. A moderated question and answer session will be held at the end of the discussion to help address any confusion or misinformation about patient access to TPOXX.